2023 (select publications)

  • Garcia J, Daniels J, Lee Y, Zhu I, Cheng K, Liu Q, Goodman D, Burnett C, Law C, Theinpont C, Alavi J, Azimi C, Montgomery G, Roybal KT*, Choi J*. Naturally occurring mutations in human T cell lymphomas enhance engineered T cell therapies. Nature.  In press. *Co-corresponding author
  • Wartewig T, Daniels J, Schulz M, Hameister E, Joshi A, Park J, Morrish E, Venkatasubramani A, Cernilogar FM, van Heijster FHA, Hundshammer C, Schneider H, Konstantinidis F, Gabler JV, Klement C, Kurniawan H, Law C, Lee Y, Choi S, Guitart J, Forne I, Giustinani J, Muschen M, Jain S, Weinstock DM, Rad R, Ortonne N, Schilling F, Schotta G, Imhof A, Brenner D, Choi J*, Ruland J*. PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma. (2023) Nature Cancer. *Co-corresponding author

2022 (select publications)

CTCLs are inhibited by negative homeostatic pathways that constrain untransformed T cells. In this case, T cell exhaustion is a powerful tumor suppressor. PD1 deletions reverse T cell exhaustion leading to more aggressive disease phenotypes in vitro and in vivo.


Figure 1.Proposed model of cell of origin driving disease pathogenesis in PCGDTL. Epidermal/dermal PCGDTL derives from the Vd1 cell whereas panniculitic PCGDTL derives from the Vd2 cell.


Figure 1. Clinical Course of Patient with DRESS Treated with Tofacitinib. 


Figure 1. (A) Mutational Burden of Skin and Selected Non-Skin Cancers for Comparison. (B) Schema Depicting Model of Convergent Development of MCPyV- and MCPyV+ MCC. 


Figure 1. Identification of Genes that Drive T Cell Lymphomagenesis. 


Figure 1. Identification of Viral and Non-Viral Neoantigens in Merkel Cell Carcinoma.


Figure 1. Identification of the Genomic Landscape of CTCL. 


  • Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, Bjornson RD, Maman Y, Wang T, Tordoff J, Carlson K, Overton JD, Liu KJ, Lewis JM, Devine L, Barbarotta L, Foss FM, Subtil A, Vonderheid EC, Edelson RL, Schatz DG, Boggon TJ, Girardi M, Lifton RP. Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 2015 Sep;47(9):1011-9. doi: 10.1038/ng.3356. Epub 2015 Jul 20. PubMed PMID: 26192916; PubMed Central PMCID: PMC4552614.
  • Hosler GA, Davoli T, Mender I, Litzner B, Choi J, Kapur P, Shay JW, Wang RC. A primary melanoma and its asynchronous metastasis highlight the role of BRAF, CDKN2A, and TERT. J Cutan Pathol. 2015 Feb;42(2):108-17. doi: 10.1111/cup.12444. Epub 2014 Dec 11. PubMed PMID: 25407517; PubMed Central PMCID: PMC4470704.




  • Lansigan F, Choi J, Foss FM. Cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 2008 Oct;22(5):979-96, x. doi: 10.1016/j.hoc.2008.07.014. Review. PubMed PMID: 18954747.






For a complete list of publications, please click on the following link:

“Grit is passion and perseverance for very long-term goals. Grit is having stamina. Grit is sticking with your future, day-in, day-out. Not just for the week, not just for the month, but for years. And working really hard to make that future a reality. Grit is living life like it’s a marathon, not a sprint.”

Angela Lee Duckworth, Grit